OrbiMed's Isaly: Biotech Slump 'Has Been Overdone'

The video discusses the biotech market slump, noting it was overdone and signs of recovery are visible. Valuation challenges are highlighted, especially for companies without profits. The focus shifts to breakthrough technologies and therapies, emphasizing their importance and rapid advancement. The video also covers trends in the IPO market, noting difficulties for nascent biotech companies but highlighting the potential for exciting technologies to secure funding.

What factors are contributing to the slowdown in IPOs for biotech companies?

Which recent biotech companies are mentioned as being noteworthy?